Research overview: robenacoxib and NSAID use in cats

Robenacoxib, a nonsteroidal anti-inflammatory drug developed with selectivity for cyclooxygenase-2 and a tissue-selective profile, was studied and licensed for managing pain and inflammation in cats, addressing the longstanding challenge of using NSAIDs safely in a species with distinctive drug metabolism and heightened sensitivity to some analgesics. This overview synthesizes the pharmacology and clinical literature rather than one citation, describing how robenacoxib targets inflammation while aiming to limit adverse effects, why NSAID use in cats requires special caution particularly regarding kidney function and dosing, and how it broadened safe options for feline pain control. It matters because cats metabolize many drugs differently and are vulnerable to NSAID toxicity, so the development of agents with improved feline safety profiles meaningfully advanced the management of acute and chronic inflammatory pain in cats.